• DOI:10.1016/j.phrs.2018.11.003
Corpus ID: 53235342

Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison

@article{Motaghi2019EtrolizumabVI,
  title={Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison},
  author={E. Motaghi and Masoumeh Ghasemi-Pirbaluti and M. Zabihi},
  journal={Pharmacological Research},
  year={2019},
  volume={139},
  pages={120–125}
}

E. Motaghi, Masoumeh Ghasemi-Pirbaluti, M. Zabihi

Published 2019

Medicine

Pharmacological Research

Objectives: There is still a need to develop new effective medications for the treatment of ulcerative colitis, particularly for patients who are intolerant or resistant to first line therapies. This article compared the efficacy and safety of etrolizumab and infliximab in moderate to severe ulcerative colitis. Methods: This meta‐analysis was performed according to the PRISMA statement protocol. A systematic literature search of three major bibliographic databases (Scopus, PubMed, and Cochran… CONTINUE READING

View on Wolters Kluwer

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed